606
Participants
Start Date
December 12, 2023
Primary Completion Date
April 30, 2026
Study Completion Date
September 30, 2026
Treat-to-target as a new treatment concept
After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
RECRUITING
Charité - Berlin University of Medicine, Berlin
RECRUITING
UKSH Campus Kiel, Kiel
RECRUITING
Medical University Hannover, Hanover
RECRUITING
University Clinic Düsseldorf, Düsseldorf
RECRUITING
Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Herne
RECRUITING
Kliniken Essen Mitte, Essen, Essen
RECRUITING
University Clinic Münster, Münster
RECRUITING
University Clinic Mainz, Mainz
RECRUITING
University Clinic Frankfurt, Frankfurt am Main
RECRUITING
University Clinic Heidelberg, Heidelberg
RECRUITING
University Clinic Freiburg, Freiburg im Breisgau
RECRUITING
LMU Munich, Munich
NOT_YET_RECRUITING
University Clinic Erlangen, Erlangen
RECRUITING
University Medical Center TU Dresden, Dresden
University Hospital Heidelberg
OTHER
German Diabetes-Center, Leibniz-Institut in Düsseldorf
OTHER
Lupus Erythematodes-Selbsthilfegemeinschaft e.V.
UNKNOWN
Heinrich-Heine University, Duesseldorf
OTHER